Table 1. Clinical and Demographic Characteristics of Patients Who Received Paclitaxel and Oxaliplatin Chemotherapy.
| Characteristics | Participants, No. (%) | P value | |
|---|---|---|---|
| Paclitaxel (n = 228) | Oxaliplatin (n = 105) | ||
| Women | 221 (96.9) | 45 (42.9) | <.001 |
| Cancer types | |||
| Breast | 138 (60.5) | 0 | <.001 |
| Colorectal | 0 | 83 (79.0) | |
| Ovarian | 37 (16.2) | 0 | |
| Endometrial | 32 (14.0) | 0 | |
| Gastrointestinal | 6 (2.6) | 10 (9.5) | |
| Pancreatic | 2 (0.9) | 10 (9.5) | |
| Cervical | 3 (1.3) | 0 | |
| Lymphoma | 0 | 1 (1.0) | |
| Unknown | 10 (4.4) | 1 (1.0) | |
| Stage | <.001 | ||
| I | 24 (10.5) | 1 (1.0) | |
| II | 82 (36.0) | 11 (10.5) | |
| III | 70 (30.7) | 47 (44.8) | |
| IV | 32 (14.0) | 40 (38.1) | |
| Undefined | 20 (8.8) | 6 (5.7) | |
| Type 2 diabetes | 18 (7.9) | 10 (9.5) | .87 |
| Carpal tunnel syndrome | 14 (6.1) | 6 (5.7) | .68 |
| Numbness and tingling before chemotherapy | 11 (4.8) | 2 (1.9) | .007 |
| Blood parameters outside normal range | |||
| Low hemoglobin | 47 (20.6) | 32 (30.5) | .05 |
| High lymphocytes | 27 (11.8) | 10 (9.5) | .59 |
| High white blood cell count | 20 (8.8) | 15 (14.3) | .16 |
| Low lymphocytes | 22 (9.6) | 8 (7.6) | .85 |
| High neutrophils | 11 (4.8) | 9 (8.6) | .23 |
| Microcytic anemia | 7 (3.1) | 11 (10.5) | .02 |
| Low neutrophils | 13 (5.7) | 1 (1.0) | .006 |
| Low white blood cell count | 13 (5.7) | 0 | .006 |
| Low albumin | 9 (3.9) | 5 (4.8) | .72 |
| Age, median (IQR), y | 57 (48-67) | 60 (50-68) | .12 |
| Months since treatment, median (IQR) | 9 (6-12) | 6 (4-11) | <.001 |
| Chemotherapy dose, mean (SD), mg/m2 | 844.6 (232.4) | 749.1 (189.0) | NA |
| Relative dose intensity, mean (SD), % | 88.6 (12.8) | 83.8 (13.4) | .03 |
| Body surface area, mean (SD), m2 | 1.81 (0.22) | 1.92 (0.23) | <.001 |
| Body mass index, mean (SD)a | 27.5 (6.6) | 27.5 (5.5) | .95 |
| White blood cells, mean (SD), × 103/μL | 7.20 (2.7) | 7.35 (2.0) | .62 |
| Neutrophils, mean (SD), × 103/μL | 4.43 (2.2) | 4.71 (1.6) | .24 |
| Lymphocytes, mean (SD), × 103/μLb | 1.96 (0.8) | 1.88 (0.9) | .17 |
| Monocytes, mean (SD), × 103/μLb | 0.52 (0.3) | 0.54 (0.3) | .15 |
| Hemoglobin, mean (SD), g/dL | 12.9 (1.2) | 12.9 (1.5) | .74 |
| Magnesium, mean (SD), mg/dL | 2.07 (0.2) | 2.02 (0.2) | .18 |
| Albumin, mean (SD), g/dL | 4.0 (0.5) | 3.9 (0.5) | .06 |
| Mean corpuscular volume, mean (SD), μm3b | 89.4 (6.4) | 86.6 (6.1) | <.001 |
| Neutrophil-to-lymphocyte ratio, mean (SD)b | 2.7 (2.9) | 3.1 (2.4) | .005 |
| Monocyte-to-lymphocyte ratio, mean (SD)b | 0.31 (0.2) | 0.34 (0.2) | .01 |
Abbreviations: IQR, interquartile range; NA, not applicable.
SI conversion factor: To convert white blood cells, neutrophils, lymphocytes, and monocytes to × 109/L, multiply by 0.001; to convert hemoglobin and albumin to g/L, multiply by 10.0; to convert magnesium to mmol/L, multiply by 0.4114; and to convert mean corpuscular volume to fL, multiply by 1.0.
a
Body mass index is calculated as weight in kilograms divided by height in meters squared.
b
Mann-Whitney U test for nonnormally distributed data.